Inhibition of BIRC5 and MCL-1 as a potential treatment strategy to overcome drug resistance in Mantle Cell Lymphoma
RNA-seq (gene expression) · human · 56 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 56 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Inhibition of BIRC5 and MCL-1 as a potential treatment strategy to overcome drug resistance in Mantle Cell LymphomaBlood cancer journal · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE312789_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1376135 and SRA study SRP651887. Searching any of these in the dataset finder brings you back here.
The grouping that defines any comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Sample titles run AKM1 … AKM56 and carry no group information.
- GSM9353289 AKM1
- GSM9353290 AKM2
- GSM9353291 AKM3
- GSM9353292 AKM4
- GSM9353293 AKM5
- GSM9353294 AKM6
- GSM9353295 AKM7
- GSM9353296 AKM8
- GSM9353297 AKM9
- GSM9353298 AKM10
- GSM9353299 AKM11
- GSM9353300 AKM12
- GSM9353301 AKM13
- GSM9353302 AKM14
- GSM9353303 AKM15
- GSM9353304 AKM16
- GSM9353305 AKM17
- GSM9353306 AKM18
- GSM9353307 AKM19
- GSM9353308 AKM20
- GSM9353309 AKM21
- GSM9353310 AKM22
- GSM9353311 AKM23
- GSM9353312 AKM24
- GSM9353313 AKM25
- GSM9353314 AKM26
- GSM9353315 AKM27
- GSM9353316 AKM28
- GSM9353317 AKM29
- GSM9353318 AKM30
- GSM9353319 AKM31
- GSM9353320 AKM32
- GSM9353321 AKM33
- GSM9353322 AKM34
- GSM9353323 AKM35
- GSM9353324 AKM36
- GSM9353325 AKM37
- GSM9353326 AKM38
- GSM9353327 AKM39
- GSM9353328 AKM40
+ 16 more — browse all 56 samples with per-sample file links →
- GSE300177 Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemia 194 samples shares inhibition, resistance, overcome
- GSE314603 Transcriptomic profiling of MCL-1 inhibitor response and resistance in mantle cell lymphoma cell lines and patient PBMCs 20 samples shares mcl-1, resistance
- GSE78220 mRNA expressions in pre-treatment melanomas undergoing anti-PD-1 checkpoint inhibition therapy 28 samples shares inhibition, treatment
- GSE303100 Dissecting Resistance to CDK4/6 Inhibition in Experimental Glioma via Genome-wide CRISPR-Cas9 Screening 24 samples shares inhibition, resistance
- GSE326661 Reprogramming engineered autologous T cells to overcome resistance in Merkel cell carcinoma [scRNA-seq] 22 samples shares resistance, overcome
- GSE231526 DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer 18 samples shares inhibition, overcome
- GSE306800 Extracellular matrix-myCAF signatures correlate with resistance to neoadjuvant aPD-L1 immune checkpoint inhibition with durvalumab + metformin in HPV+ HNSCC 18 samples shares inhibition, resistance
- GSE303446 Beyond CD30 Targeting: Brentuximab Vedotin Triggers Immunogenic Cell Death and Antitumor Immunity in Mycosis Fungoides, Overcoming Resistance via BCL2 Inhibition 13 samples shares inhibition, resistance
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.